RT @RichardPAConway: FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to
Tweet Content
FitzGerald et al. PsA patients with higher levels of IL-23-IL-17 pathway biomarkers more likely to benefit from TYK2i deucravacitinib @RheumNow #ACR22 Abstr#2133 https://t.co/eVq4XQgX5l https://t.co/HZlTS5OZ2s
Links
Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selec…
https://acrabstracts.org/abstract/baseline-biomarkers-predict-better-responses-…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off